InspireMD Q4 revenue jumps 71.6% to $1.76M; net loss $0.16 per share

InspireMD, Inc.

Record Q4 CGuard EPS revenue of $1.76M, up 71.6% YoY; 3,107 stents sold (+74.5%).
C-GUARDIANS trial showed 0.95% DSMI rate at 30 days; PMA submission expected mid-2024.
CE Mark recertified under EU MDR, enabling new product development pathway.
CMS expanded CAS coverage to asymptomatic and standard-risk patients, widening U.S. market.
Cash and equivalents $39.0M at Dec 31, 2023, up from $17.8M a year earlier.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

InspireMD, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $1,761,000.

Period: the fourth quarter ended December 31, 2023
Revenue: $1,761,000
Result: reported results

Exact text from the filing

For the fourth quarter of 2023, total revenue increased 71.6%, to $1,761,000, from $1,026,000 during the fourth quarter of 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

InspireMD, Inc. reported financial results for the full-year ended December 31, 2023.

Period: the full-year ended December 31, 2023
Result: reported results

Exact text from the filing

InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuardTM Embolic Prevention System (EPS) for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced financial and operating results for the fourth quarter and full-year ended December 31, 2023.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

InspireMD, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-008941

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.